Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment
- 8 September 2020
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (32), 3740-3742
- https://doi.org/10.1200/jco.20.01755
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyClinical Cancer Research, 2020
- Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology, 2020
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialThe Lancet Oncology, 2020
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerThe New England Journal of Medicine, 2019
- The Tumor Suppressor PALB2: Inside OutTrends in Biochemical Sciences, 2019
- Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumJCO Precision Oncology, 2018
- Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterationsAnnals of Oncology, 2018
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerThe New England Journal of Medicine, 2015
- Breast-Cancer Risk in Families with Mutations in PALB2The New England Journal of Medicine, 2014
- Breast-Cancer Risk in Families with Mutations in PALB2The New England Journal of Medicine, 2014